Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity

Aaron Kaviani, Rose Khavari

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

Intradetrusor injection of botulinum toxin A (BTX-A) is an effective option for managing patients with neurogenic detrusor overactivity (NDO) who do not respond to or tolerate oral pharmacologic agents. There is level I evidence that intradetrusor injection of onabotulinumtoxinA for refractory NDO in patients with multiple sclerosis and spinal cord injury is associated with a significantly greater achievement of goals and improved performance in urodynamic studies than placebo. Pilot studies or small case series support BTX-A for NDO in patients with Parkinson's disease and cerebrovascular accident. BTX-A seems to be effective in children with myelomeningocele. However, no adult data exists.

Original languageEnglish (US)
Pages (from-to)463-474
Number of pages12
JournalUrologic Clinics of North America
Volume44
Issue number3
DOIs
StatePublished - Aug 2017

Keywords

  • Botulinum toxin
  • Detrusor overactivity
  • Multiple sclerosis
  • Myelomeningocele
  • Neurogenic
  • Overactive bladder
  • Parkinson's disease
  • Urinary incontinence

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity'. Together they form a unique fingerprint.

Cite this